Delivery Technologies for Cancer Immunotherapy
Rachel S. Riley, Carl H. June, Robert Langer, Michael J. Mitchell.DOI 10.1038/s41573-018-0006-z
Read the original ↗Summary
Immunotherapy has become powerful but broad implementation limited by inability to control immune modulation; serious adverse effects including autoimmunity, nonspecific inflammation. Need delivery technologies to improve efficacy and safety. Numbers.
Purpose: Immunotherapy has become powerful but broad implementation limited by inability to control immune modulation; serious adverse effects including autoimmunity, nonspecific inflammation. Need delivery technologies to improve efficacy and safety.
Hypothesis: If advanced biomaterials/delivery systems (nanoparticles, implants, scaffolds, cell-based platforms) are engineered for targeted/localized/controlled release, then cancer immunotherapies can be harnessed with improved potency and reduced toxic side effects.
Aims: - Overview main classes of cancer immunotherapy and clinical status, advantages/disadvantages. - Review novel delivery platforms to overcome clinical translation challenges. - Analyse opportunities/challenges integrating delivery technologies into cancer immunotherapy. - Discuss clinical translation and future directions.
Delivery system: List classes: nanoparticles/conjugates; biomaterials localised; T cell therapy delivery. Specific examples.
Approach: Narrative review; preclinical/clinical literature; mouse models etc.
Key methods: Techniques across cited studies: flow cytometry, IVIS, tumour growth/survival, cytokine assays, microscopy, MRI/PET for EPR, etc.
Key results: Numbers.
Interpretation: As above.
Limitations: As above. Need maybe mention "Table 1" FDA approved immunotherapies, "Table 2" characteristics. Good. Need no additional commentary. Final answer. Ensure not too long. Could be around 1500 words? Desired oververbosity 5 maybe ~1000-1500. Let's produce.
Related articles
RSC pharmaceutics
Orthogonal ensemble and single-particle characterisation of antisense oligonucleotide lipid nanoparticles
Discover nanoLipid nanoparticle-based mRNA delivery system for cancer management
Molecular cancersiRNA-mediated mismatch repair disruption synergizes with oxaliplatin to restore immune surveillance in microsatellite-stable colorectal cancer
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.